Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.

@article{Dayd2009TumorBI,
  title={Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20.},
  author={David Dayd{\'e} and David Ternant and Marc Ohresser and St{\'e}phanie Lerondel and Sabrina Pesnel and Herv{\'e} Watier and Alain le Pape and Pierre Bardos and Gilles Paintaud and Guillaume Cartron},
  journal={Blood},
  year={2009},
  volume={113 16},
  pages={3765-72}
}
Clinical studies have shown a large interindividual variability in rituximab exposure and its significant influence on clinical response in patients receiving similar doses of antibody. The aim of this study was to evaluate the influence of tumor burden on dose-concentration-response relationships of rituximab. Murine lymphoma cells (EL4, 8 x 10(3)), transduced with human CD20 cDNA and transfected with luciferase plasmid (EL4-huCD20-Luc), were intravenously injected into C57BL/6J mice. Tumor… CONTINUE READING